Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perindopril and Telmisartan in NAFLD
NCT02213224Phase 4Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Aug 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of perindopril and telmisartan in non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Controlled Attenuation Parameter at 48 weeks. Status: unknown.
02
Drugs
perindopriltelmisartan
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02213224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213224.